Verona Pharma plc (VRNA)
NASDAQ: VRNA · Real-Time Price · USD
67.57
+0.04 (0.06%)
May 13, 2025, 4:00 PM - Market closed
Verona Pharma Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Operating Revenue | 113.52 | 42.26 | - | - | 40 | - | Upgrade
|
| Other Revenue | 5.02 | 0.02 | - | 0.46 | - | - | Upgrade
|
| Revenue | 118.54 | 42.28 | - | 0.46 | 40 | - | Upgrade
|
| Revenue Growth (YoY) | - | - | - | -98.86% | - | - | Upgrade
|
| Cost of Revenue | 5.99 | 2.58 | - | 0.35 | - | - | Upgrade
|
| Gross Profit | 112.55 | 39.7 | - | 0.11 | 40 | - | Upgrade
|
| Selling, General & Admin | 198.43 | 149.75 | 50.35 | 26.58 | 33.91 | 29.77 | Upgrade
|
| Research & Development | 48.85 | 40.97 | 16.11 | 39.65 | 63.78 | 36.24 | Upgrade
|
| Operating Expenses | 247.28 | 190.72 | 66.47 | 66.23 | 97.68 | 66.01 | Upgrade
|
| Operating Income | -134.73 | -151.03 | -66.47 | -66.12 | -57.68 | -66.01 | Upgrade
|
| Interest Expense | -32.15 | -23.54 | -2.06 | -0.52 | -0.34 | -0.04 | Upgrade
|
| Interest & Investment Income | 15.78 | 15.26 | 12.76 | 2.82 | 0.01 | 0.12 | Upgrade
|
| Currency Exchange Gain (Loss) | 0.52 | -0.17 | 1.87 | -3.82 | 0.18 | 2.06 | Upgrade
|
| Other Non Operating Income (Expenses) | - | - | - | - | 2.25 | -1.14 | Upgrade
|
| EBT Excluding Unusual Items | -150.59 | -159.48 | -53.9 | -67.63 | -55.59 | -65 | Upgrade
|
| Other Unusual Items | -4.06 | -3.65 | - | -0.82 | - | - | Upgrade
|
| Pretax Income | -154.65 | -163.13 | -53.9 | -68.45 | -55.59 | -65 | Upgrade
|
| Income Tax Expense | 9.3 | 10.29 | 0.47 | 0.25 | -0.02 | 0.15 | Upgrade
|
| Net Income | -163.94 | -173.42 | -54.37 | -68.7 | -55.57 | -65.15 | Upgrade
|
| Net Income to Common | -163.94 | -173.42 | -54.37 | -68.7 | -55.57 | -65.15 | Upgrade
|
| Shares Outstanding (Basic) | 83 | 82 | 79 | 66 | 59 | 33 | Upgrade
|
| Shares Outstanding (Diluted) | 83 | 82 | 79 | 66 | 59 | 33 | Upgrade
|
| Shares Change (YoY) | 3.21% | 2.86% | 19.86% | 11.81% | 79.97% | 149.64% | Upgrade
|
| EPS (Basic) | -1.98 | -2.13 | -0.69 | -1.04 | -0.94 | -1.98 | Upgrade
|
| EPS (Diluted) | -2.02 | -2.16 | -0.72 | -1.04 | -0.94 | -1.98 | Upgrade
|
| Free Cash Flow | -121.25 | -122.78 | -50.22 | -59.89 | -33.27 | -45.16 | Upgrade
|
| Free Cash Flow Per Share | -1.47 | -1.51 | -0.63 | -0.91 | -0.56 | -1.37 | Upgrade
|
| Gross Margin | 94.95% | 93.89% | - | 24.45% | 100.00% | - | Upgrade
|
| Operating Margin | -113.66% | -357.22% | - | -14435.81% | -144.21% | - | Upgrade
|
| Profit Margin | -138.31% | -410.18% | - | -15000.22% | -138.92% | - | Upgrade
|
| Free Cash Flow Margin | -102.29% | -290.41% | - | -13076.64% | -83.17% | - | Upgrade
|
| EBITDA | -133.64 | -149.97 | -65.79 | -65.48 | -57.05 | -65.39 | Upgrade
|
| EBITDA Margin | -112.74% | - | - | - | -142.63% | - | Upgrade
|
| D&A For EBITDA | 1.09 | 1.06 | 0.68 | 0.64 | 0.63 | 0.62 | Upgrade
|
| EBIT | -134.73 | -151.03 | -66.47 | -66.12 | -57.68 | -66.01 | Upgrade
|
| EBIT Margin | -113.66% | - | - | - | -144.21% | - | Upgrade
|
| Revenue as Reported | 118.54 | 42.28 | - | 0.46 | - | - | Upgrade
|
Updated Apr 29, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.